Latest Close
$2.41
News
ADAG
Adagene Inc. News
This news view pulls recent coverage and headlines tied to ADAG.
1y Change
$0.62 (+34.64%)
Market Cap
$161,815,472.00
Sector
Healthcare
Industry
Biotechnology
Recommendation
strong_buy
Adagene Eyes Phase II Data for Masked CTLA-4 Therapy in MSS Colorectal Cancer
MarketBeat • Oct 25, 2026
Read articleAdagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 Catalysts
MarketBeat • Oct 16, 2026
Read articleAdagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference
GlobeNewswire • Oct 14, 2026
Read articleAdagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
GlobeNewswire • Sep 22, 2026
Read articleAdagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
GlobeNewswire • Sep 10, 2026
Read articleChardan Initiates Adagene at Buy With $9 Price Target
MT Newswires • Sep 10, 2026
Read article